Foresight Diagnostics, a cancer diagnostics company and CLIA-registered laboratory led by CEO Jake Chabon, has secured funding to expedite the clinical development and commercialization of its cancer recurrence testing platform, PhasED-Seq. The company’s liquid biopsy testing platform measures minimal residual disease (MRD) to furnish physicians and biopharmaceutical companies with essential data to devise customized treatment options for patients with hematologic malignancies and solid tumors
Renewable Energy Developer Granite Source Power Secures $40M in Funding for Battery Storage Expansion
Portsmouth-based battery storage developer, Granite Source Power (GSP), has successfully secured $40 million in Strategic Growth Capital to fuel its...
